This article is for informational purposes only and does not constitute medical or legal advice. Cannabis laws vary by jurisdiction. Consult a healthcare provider before using cannabinoid products, especially if taking medications.
By CaliforniaCannabinoids Editorial Team | Last verified: July 2026
What It Is: Chemical Classification and Natural Source
Cannabinol (CBN) is a C21H26O2 phytocannabinoid produced in cannabis and hemp plants, but in minimal quantities compared to THC, CBD, and CBG. Unlike THC and CBD, which are primary cannabinoids synthesized directly in the plant’s resin glands, CBN is a secondary metabolite—it forms when THC oxidizes and degrades over time through exposure to light, heat, and oxygen. This oxidation occurs naturally during plant maturation, storage, and processing.
In raw cannabis flower, CBN concentrations typically range from 0.1% to 1%. However, aged cannabis material and stored cannabis products often contain significantly higher CBN levels. This is why older cannabis is traditionally associated with more sedating effects than freshly harvested material.
CBN was one of the first cannabinoids to be identified in the 1890s, predating the discovery of THC’s psychoactive properties by several decades. It exists in full-spectrum cannabis extracts, distillates, and isolate form. CBN can also be synthesized from THC degradation in the laboratory, allowing manufacturers to create standardized CBN products independent of plant genetics.
How It Works: Receptor Binding and Mechanism of Action
CBN interacts with the endocannabinoid system through multiple pathways, though with lower binding affinity than THC. Research indicates CBN acts as a partial agonist at both CB1 and CB2 receptors—meaning it activates these receptors but with moderate potency. This partial agonist profile may explain why CBN produces milder psychoactive effects than THC’s full agonism at CB1.
Beyond classical cannabinoid receptors, CBN demonstrates activity at transient receptor potential (TRP) channels, particularly TRPV1, which regulates pain, temperature, and inflammation. This multi-target activity distinguishes CBN from single-pathway cannabinoids and may underlie reports of pain relief and anti-inflammatory effects.
CBN also inhibits cytochrome P450 enzyme CYP2C9, which is clinically significant for drug interactions (discussed below). The precise mechanism driving CBN’s purported sedating effects remains incompletely characterized in humans, though animal models suggest CB1 activation in sleep-regulating brain regions may play a role.
What the Research Shows: Evidence-Based Effects and Limitations
Sleep and Sedation
Sleep is the most commonly cited benefit for CBN, supported by preclinical data and anecdotal reports but limited human clinical evidence. A foundational animal study (2012) found that CBN prolonged sleep duration in mice, with effects comparable to diazepam at higher doses. However, this study was small and did not establish a dose-response relationship in humans.
More recent surveys of cannabis consumers report that aged cannabis and CBN-dominant products produce sedating effects. However, these are observational reports, not controlled trials. As of 2026, no large-scale, placebo-controlled human clinical trials specifically isolating CBN’s effects on sleep duration or quality have been published in peer-reviewed journals. Evidence grade: Preliminary (animal models + consumer reports).
Pain and Anti-Inflammation
Preclinical studies show CBN reduces inflammatory markers in cell cultures and animal models of inflammation. The TRPV1 pathway activation may contribute to analgesic effects. However, human pain trials are absent from the literature. Claims that CBN is effective for arthritis, neuropathy, or chronic pain are not supported by clinical evidence in humans. Evidence grade: Preclinical only.
Antibacterial Activity
In vitro studies indicate CBN has activity against methicillin-resistant Staphylococcus aureus (MRSA) and other bacteria, though at concentrations much higher than would be achievable systemically in human use. No human clinical trials exist. Evidence grade: Laboratory (in vitro) only.
Appetite Stimulation
CBN demonstrates weaker appetite-stimulating effects than THC in animal models, but human data are absent. Evidence grade: Preclinical only.
Glaucoma and Intraocular Pressure
Early in vitro and animal studies suggested CBN might reduce intraocular pressure, a hallmark of glaucoma. However, no human trials have been conducted, and this area of research has been largely superseded by work on other cannabinoids. Evidence grade: Preclinical only.
Critical Note on Evidence Gap: Most cannabinoid research, including CBN, is conducted in cell cultures or animal models. Human clinical trials are rare, often small, short-term, and frequently funded by industry. Be cautious of marketing claims that exceed the evidence base. CBN remains a promising research compound rather than a proven therapeutic agent.
Delivery Methods, Bioavailability, and Onset Times
Inhalation (Smoking/Vaping)
Inhaled CBN reaches the bloodstream within seconds to minutes, with peak plasma levels typically occurring 3–10 minutes post-inhalation. Duration is 2–4 hours for psychoactive effects, though anti-inflammatory or analgesic effects may persist longer. Bioavailability ranges from 10–35% depending on smoking technique and device efficiency.
Sublingual (Tinctures and Sprays)
Sublingual CBN products dissolve under the tongue, allowing absorption through mucous membranes. Onset is typically 15–45 minutes, with duration of 4–8 hours. Bioavailability is estimated at 13–19%, higher than oral but lower than inhalation due to first-pass hepatic metabolism.
Oral (Edibles and Capsules)
Ingested CBN undergoes hepatic metabolism, resulting in slower onset (45 minutes to 2 hours) but longer duration (6–12 hours). Bioavailability is 5–20% and highly variable depending on food intake and individual metabolism. The liver metabolizes CBN to hydroxylated and carboxylated metabolites, some of which may have their own pharmacological activity.
Topical
CBN in creams, balms, and transdermal patches has limited systemic absorption due to skin barrier properties. Topical application likely produces local rather than systemic effects. Onset for perceived benefit may be 30 minutes to several hours; duration is variable and understudied.
Legal and Regulatory Status
Federal Level
Under the 2018 Farm Bill, hemp-derived cannabinoids including CBN are permitted at the federal level if the final product contains no more than 0.3% Delta-9-THC on a dry-weight basis. CBN itself is not a controlled substance under federal law. This permits the sale of CBN isolates, distillates, and full-spectrum hemp extracts in all states, though state law supersedes federal law in practice.
California
California permits CBN in licensed cannabis products (both cannabis-derived and hemp-derived, if compliant with Proposition 64 testing and labeling requirements). Hemp-derived CBN products are also legal if they comply with state Department of Cannabis Regulation guidelines and contain ≤0.3% Delta-9-THC. All products must carry warning labels and pass third-party testing for potency, pesticides, heavy metals, and microbial contaminants.
State Variation
Most states that permit hemp-derived cannabinoids allow CBN. However, a few states have moved to restrict minor cannabinoids or require specific licensing. Always verify current state regulations, as cannabis policy changes frequently. Check our cannabinoid legal status guide for the latest updates.
Who Should Consider CBN — and Who Should Avoid It
Potential Users
CBN may be worth exploring for individuals seeking mild sedative support without high THC intoxication. Those sensitive to THC’s psychoactive effects but interested in cannabis-based sleep or relaxation support may find lower-THC, CBN-rich products more tolerable. However, expectations should be grounded in the preliminary nature of human evidence.
Individuals using CBN should track subjective effects (sleep onset, sleep duration, daytime grogginess) over 2–4 weeks to assess personal response, as controlled trials are absent.
Who Should Avoid or Use Caution
CYP2C9 Substrate Drug Users: CBN inhibits CYP2C9, which metabolizes warfarin (Coumadin), NSAIDs (ibuprofen, naproxen), clopidogrel (Plavix), and other drugs. Concurrent use may elevate drug plasma levels and increase adverse effects. Medical supervision is essential if combining CBN with any CYP2C9-metabolized medication.
Pregnancy and Lactation: Limited safety data; most cannabinoid products are advised against during pregnancy and breastfeeding due to cannabinoid passage into breast milk and potential effects on fetal neurodevelopment. Consult an obstetric provider.
Driving and Machinery Operation: Although CBN is less intoxicating than THC, mild psychoactive effects and sedation may impair reaction time and cognition. Do not drive or operate machinery within 2–4 hours of CBN use.
Cannabis Use Disorder History: Individuals with personal or family history of cannabis dependence should consult a healthcare provider before regular CBN use.
Liver Disease: CBN is hepatically metabolized; those with cirrhosis or significant hepatic impairment should avoid CBN or use only under medical guidance.
Mental Health Conditions: Though CBN is less psychoactive than THC, cannabinoids can exacerbate anxiety, paranoia, or psychotic symptoms in vulnerable individuals. Those with schizophrenia, bipolar disorder, or severe anxiety should consult a psychiatrist.
Safety and Side Effects
Common Side Effects
At typical doses (5–25 mg), reported side effects are mild and infrequent: dry mouth, mild drowsiness, slight dizziness, and minor appetite changes. These generally resolve within hours and are less common than with equivalent THC doses.
Psychoactive Effects
CBN produces mild “high” or altered mental state at moderate to high doses, though significantly less pronounced than THC. Some users report a subtle euphoria or detachment; others notice none. Individual sensitivity varies widely. First-time users should start with low doses (2.5–5 mg) to assess response.
Sedation and Impairment
Higher doses (20–50+ mg) may produce marked sedation. This is undesirable for daytime use but may benefit nighttime sleep support. Sedation can impair motor coordination and cognitive function; do not drive after CBN use.
Drug Interactions: The CYP2C9 Factor
This is the most clinically significant interaction. CBN inhibits CYP2C9 metabolism, increasing plasma concentrations of:
- Warfarin (Coumadin): Risk of bleeding; requires INR monitoring
- NSAIDs (ibuprofen, naproxen, meloxicam): Increased GI upset, ulcer risk
- Clopidogrel (Plavix): Reduced antiplatelet effect (paradoxically)
- Phenytoin (Dilantin), Phenobarbital: Potential increased levels and toxicity
- Sulfonylureas (glipizide, glyburide): Increased hypoglycemia risk
If you take any of these medications, consult your physician or pharmacist before using CBN products. Do not self-treat; medical monitoring may be necessary.
Tolerance and Dependence
Regular cannabinoid use may produce tolerance (diminished response over time). Dependence liability is low compared to opioids or benzodiazepines but is not absent. Some regular users report mild withdrawal effects (sleep disruption, irritability) upon cessation. Tolerance often reverses within 1–4 weeks of abstinence.
Contamination and Product Safety
CBN products should be third-party tested for potency, residual solvents (if extracted), pesticides, heavy metals, and microbial contaminants. Products from unlicensed sources may contain harmful adulterants or mislabeled potency. Always request certificates of analysis (CoA) from reputable sellers.
Key Takeaway: What CBN Is, and What It Isn’t
Cannabinol is a mildly psychoactive secondary cannabinoid that shows promise in animal models and preliminary human observations for sleep support and possibly pain management. However, evidence in humans is minimal—most published research is preclinical. Current uses of CBN are largely driven by anecdotal consumer reports and industry interest rather than robust clinical data.
CBN is legal at the federal level (in hemp form) and in California (if properly tested and labeled), making it accessible. However, legal availability should not be conflated with proven efficacy or universal safety. The most significant clinical concern is CYP2C9 inhibition, which can alter blood levels of common medications including warfarin and NSAIDs.
If you are interested in trying CBN, start with a low dose (5 mg or less), track subjective effects over several weeks, and—critically—consult your healthcare provider before use if you take warfarin, NSAIDs, antiplatelet drugs, anticonvulsants, sulfonylureas, or other CYP2C9 substrates. CBN may eventually find a therapeutic niche, but current hype exceeds current evidence.
For balanced context, explore our guide to cannabinoid receptor pharmacology and our overview of minor cannabinoid research frontiers to understand where CBN fits in the broader cannabinoid landscape. And remember: cannabis science is evolving rapidly, and recommendations may change as human clinical trials emerge.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before starting any new supplement or health program, especially if you have existing medical conditions or take prescription medications.